Krista Rossi

Using relevant clinical trial data, investigators created a price tag of about $6300 annually for the very effective, often costly inhibitor.

At 12 weeks post treatment per protocol analysis with 8 weeks of glecaprevir/pibrentasvir treatment, patients with hepatitis C virus genotypes 1, 2, 4, 5 and 6 achieved a sustained virologic response.

Norah Terrault, MPH, MD, addresses the many unanswered questions and data surrounding cannabis use in liver disease.

A launderable mattress barrier has shown to decrease hospital-onset Clostridium difficile infections.

Not sure what’s been recalled, withdrawn from the market, or had safety updates? Catch up on the US Food and Drug Administration’s (FDA's) recalls and safety news from this past week.

The FDA has approved revefenacin (YUPELRI) for the maintenance treatment of chronic obstructive pulmonary disease.

Glenn Tillotson, PhD, highlights possible treatment options besides antibiotics that may be worth evaluating for the infectious disease.

Data from a new study indicate that trauma is an independent risk factor for cardiovascular disease in sexual minority women, suggesting it should be screened for as a risk factor in this population.

Dale Gerding, MD, highlights newest and most promising treatment approaches and preventions for C difficile.

Catia Mato Ferreira, PhD, global medical lead of Medical Affairs at Pfizer discussed the preventive potential of the C difficile vaccine that is currently in development in a phase 3 trial.

Nicola Petrosillo, MD, discusses current controversies in C difficile prevention and treatment.

A new, fundamental biological process in CLN8 disease, a form of Batten disease, has been discovered by a team of investigators from Baylor College of Medicine.

Investigators have found an association between opioid use and cardiovascular mortality.

The FDA has accepted Sanofi’s supplemental biologics license application (sBLA) for priority review of dupilumab (Dupixent) in patients aged 12 to 17 years with moderate-to-severe atopic dermatitis.

Cannabidiol (Epidiolex), the first FDA-approved plant-derived cannabinoid medicine in the United States, is now available by prescription for patients with seizures associated with Lennox-Gastaut syndrome or Dravet syndrome.

Not sure what’s been recalled, withdrawn from the market, or had safety updates? Catch up on the US Food and Drug Administration’s (FDA's) recalls and safety news from this past week.

The FDA has approved sufentanil sublingual tablet (Dsuvia) as a pain management therapy.

Aquestive Therapeutics’ clobazam (SYMPAZAN) oral film has been approved by the US Food and Drug administration (FDA) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged 2 years or older.

This approval marks the first and only oral film approved by the FDA for the treatment of seizures associated with Lennox-Gastaut syndrome.

New data shows patients with rheumatoid arthritis do not change their current treatment to reach a “treat-to-target” goal for low disease activity.

There are 3 FDA-approved medications available to treat opioid use disorder, and different treatment approaches that can aid patients on the road to recovery.

Patients with severe scleroderma who were treated with hematopoietic stem cell transplantation showed significant improvement in long-term outcomes such as survival and functional status.

Robert Chen, MD, and Hodgkin’s lymphoma patient, Jeremy Hernandez, speak on the challenges of receiving and treating a rare cancer diagnosis in young adults.

The FDA has approved Sandoz’s biosimilar, Hyrimoz (adalimumab-adaz), for the treatment of patients with rheumatoid arthritis, juvenile idiopathic arthritis in patients aged 4 years and older, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis, and plaque psoriasis.

Martha L. Twaddle, MD, reviews new updates in the 4th edition of National Clinical Guidelines for Palliative Care.

Added stigma further burdens the treatment of patients with opioid use disorder, but the medical community can do something about it.

The FDA has approved Johnson & Johnson’s canagliflozin (INVOKANA) for patients with type 2 diabetes who have established cardiovascular disease in order to reduce the risk of major adverse cardiovascular events, such as heart attack, stroke, or death.

The US Food and Drug Administration has approved TherapeuticsMD's TX-001HR (BIJUVA) for the treatment of moderate to severe vasomotor symptoms due to menopause in women with a uterus.

Sodium oxybate (Xyrem) has been approved by the FDA for the treatment of cataplexy and excessive daytime sleepiness in pediatric patients aged 7 to 17 years old with narcolepsy.

Lindsey Jennings, MD, MPH, and Carolyn Bogdon, MSN, FNP-BC, of Medical University of South Carolina discuss the challenges facing health care providers who are on the front line of battling the opioid epidemic.